RayBiotech and AnaSpec Sign Licensing Agreement for HiLyte™ Dyes
News Sep 16, 2008
AnaSpec and RayBiotech have announced a licensing agreement that will allow RayBiotech to label antibodies with AnaSpec HiLytePlus™ and HiLyte Fluor™ dyes and integrate into protein and antibody arrays.
HiLytePlus™ and HiLyte Fluor™ are AnaSpec's proprietary series of high performance fluorescent dyes optimized for long wavelength biomarker labeling.
"RayBiotech is a respected provider of innovative products for life science research," noted Dr. Anita Hong, AnaSpec's president. "In collaboration with RayBiotech, we are pleased to extend the performance advantages of our HiLyte™ dyes to a broader spectrum of researchers."
"Knowing the full spectrum of fluorescent dye options available, we have incorporated the HiLytePlus™ and HiLyte Fluor™ series of fluorescent dyes into our antibodies, protein and antibody arrays," stated Dr. Ray (Ruo-Pan) Huang, Ray Biotech’s president. "We are pleased to work with AnaSpec to add the additional value of high-performance labeling options and detection method to our customers."
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE